Implant-supported Rehabilitation With SPAL Technique or Soft Tissue Augmentation

Bone Loss, Alveolar Clinical Trial

— SPALvsSTA  

Official title:

Implant-supported Rehabilitation of Atrophic Edentulous Sites With a Novel, Simplified Technique for Bone Augmentation or Soft Tissue Augmentation: a Randomized Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05610748
• Other study ID #: FIN-RER_BU_2020_45
• Status: Recruiting
• Phase: Phase 4
• Start date: July 1, 2022
• Est. completion date: June 30, 2024

Study information

• Verified date: November 2022
• Source: Università degli Studi di Ferrara
• Contact: Leonardo Trombelli, Principal Investigator
• Phone: +39 0532 688507
• Email: leonardo.trombelli[@]unife.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary aim of the present study is to compare the Sub-periosteal Peri-implant Augmented Layer (SPAL) technique and soft tissue augmentation (STA), performed simultaneously to implant placement, in terms of (i) implant survival rate and (ii) health/disease condition of the peri-implant tissues at 6 and 12 months following implant loading. The secondary aim of the project will be to compare the SPAL technique and STA in terms of intra- and post-operative morbidity.

The study is designed as a single-blind, parallel-arm, randomized clinical trial. Patients will be recruited and treated at the Operative Unit of Dentistry, Azienda Unità Sanitaria Locale (A.U.S.L.) of Ferrara, Italy, and one University center (Research Centre for the Study of Periodontal and Peri-implant Diseases, University of Ferrara, Italy). Each patient will contribute the study with one sextant ("experimental sextant"). Each eligible patient will be randomly assigned to receive SPAL technique or STA according to a computer-generated randomization list. Surgical procedures will be performed by experienced periodontal and implant surgeons. Two calibrated, blinded examiners will take care of the assessment of clinical and radiographic parameters, Case Report Form (CRF) filling, as well as data extraction from CRFs for the preparation of the study database.

The proportion of patients free from peri-implantitis at 12 months following loading will be the primary outcome variable of the study. The proportion of patients with complete resolution of the bone dehiscence (BD), dimensional variations and 12-months characteristics of BD, and patient-reported outcome measures will be the secondary outcomes. The design will test two hypotheses, with a non-inferiority trial in terms of primary outcome and a superiority trial in terms of secondary outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: June 30, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Patient-specific inclusion criteria

• age=21years;

• good physical status (ASA1 and ASA2 according to Physical Status Classification System) (American Society of Anesthesiologists, 2010);

• systemic and local conditions compatible with implant placement and experimental procedures;

• indication to a fixed, implant-supported prosthetic rehabilitation with hard or soft tissue reconstructive procedures as part of the comprehensive oral rehabilitation plan;

• patient willing and fully capable to comply with the study protocol.

Sextant-specific inclusion criteria

To be considered as experimental, a sextant will have to fulfill all the following criteria:

• including at least one healed (i.e., = 6 months elapsed from tooth loss) edentulous site;

• horizontal dimension of the edentulous ridge compatible with the primary stability of an implant of at least 3.5 mm in diameter;

• expected peri-implant buccal BD characterized by a height (measured as the apico-coronal height of the exposed implant surface) = 5 mm or a thin (< 1 mm) peri-implant buccal bone plate as diagnosed on tridimensional planning for guided implant placement.

Patient will not be eligible for the study if presenting at least one of the following exclusion criteria:

Patient-specific exclusion criteria

• current heavy smoking (=20 cigarettes/day for =6 months prior to and at the time of the surgical procedure);

• untreated periodontal disease prior to implant placement;

• history of radiation therapy in the head and neck area;

• history of chemotherapy;

• systemic disease or conditions with a documented effect on bone metabolism and/or osseous healing;

• past (within 6 months prior to enrolment in the study) or current treatment with any medication with a documented effect on bone metabolism and/or osseous healing;

• documented allergy to dental materials involved in the experimental protocol;

• pregnancy or lactation;

• history of drug or alcohol abuse.

Moreover, participants immediately exited the study upon:

• request to withdraw from further participation;

• development of acute dental, peri-implant or oral conditions requiring treatment;

• development of conditions conflicting with the inclusion criteria listed above;

• failure to comply with study instructions/requirements.

Site specific exclusion criteria

• presence of either a buccal BD > 5 mm in depth or a thick (= 1 mm) peri-implant buccal bone plate as clinically assessed with a periodontal probe immediately after implant placement;

• presence of endodontic lesions at teeth adjacent to the implant site;

• previous bone augmentation/preservation procedures at the designated implant areas;

• need for vertical bone augmentation.

Related Conditions & MeSH terms

• Alveolar Bone Loss
• Alveolar Ridge Enlargement
• Bone Loss, Alveolar
• Dehiscence

Intervention

Procedure:
• Sub-Periosteal Peri-implant Augmented Layer technique
In patients assigned to the SPAL group, the management of the soft tissues will be performed according to the SPAL technique as originally described by Trombelli et al. (2018). Implant site preparation will be performed using a set of calibrated guided surgery steel burs under copious sterile saline irrigation. Implants will be placed, and a healing abutment will be positioned and screwed. The space underneath the periosteal layer will be then filled with a deproteinized bovine bone mineral (DBBM) graft. A sterile viscoelastic gel (SVG) based on polynucleotides and hyaluronic acid (REGENFAST®, Mastelli Srl, Sanremo, Italia) will be combined with the bone graft. The periosteal layer will be then secured to the oral flap by mean of 6/0 resorbable internal mattress sutures. SVG wil be placed underneath the mucosal layer and the latter will be coronally advanced and stabilized a using 6/0 resorbable internal mattress and sling sutures.
• Soft tissue augmentation
In patients assigned to the STA group, flap management will be performed as described by Stefanini et al. (2016). Implant site preparation will be performed according to the same procedures described for the SPAL group. SVG will be placed underneath the buccal flap and the latter will be then released from tension by means of periosteal and muscular incisions, and will be coronally advanced and adapted to the healing abutment with a 6/0 resorbable sling suture. Interrupted sutures will be used to accomplish primary intention closure in the interproximal areas.

Locations

Country	Name	City	State
Italy	Polo Odontoiatrico	Ferrara

Sponsors (2)

Lead Sponsor	Collaborator
Università degli Studi di Ferrara	Azienda USL Ferrara

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients free from peri-implantitis	Proportion of patients free from peri-implantitis (diagnosed according to the criteria described by Berglundh et al. 2018) at 12 months following loading	12-month visit
Secondary	Complete resolution of bone dehiscence (BD)	Proportion of patients with complete resolution of BD as evaluated on CT/CBCT scan at 12 months following surgery	12-month visit
Secondary	Changes in height and width of bone dehiscence (BD)	Variations in height and width of bone dehiscence (BD) (as evaluated on CT/CBCT scan) occurred between pre-surgery visit 12-month visits	Pre-surgery and 12-month visits
Secondary	Height and width of the residual bone dehiscence (BD)	Height and width of bone dehiscence (BD) as evaluated on CT/CBCT scan at 12-month visit	12-month visit
Secondary	Pain	Level of pain recorded in the evening at day 0, +1, +2, +3, +4, +7 and +14 on a 100-mm visual analogue scale (VAS) ranging from "0-no pain" to "100-worst pain imaginable"	Day 0, +1, +2, +3, +4, +7 and +14 following surgery
Secondary	Dose of rescue anti-inflammatory drug	Dosage of rescue anti-inflammatory drug (i.e. number of ibuprofen 600 mg tablets) and other types of medications taken from the day of surgery to the 14th postoperative day, as recorded daily on a medication diary.	First 14 days following surgery
Secondary	Discomfort	Level of discomfort, as recorded at day 0 (evening), +1, +2, +3, +4, +7 and +14 on a 5-point rating scale ranging from "no discomfort" to "very high discomfort"	Day 0, +1, +2, +3, +4, +7 and +14 following surgery
Secondary	Limitations in daily functions	Limitations in daily functions (i.e., swallowing, continuing daily activities, eating, speaking, opening the mouth, sleeping), as recorded at day 0 (evening), +1, +2, +3, +4, +7 and +14 on a 5-point rating scale ranging from "no limitations" to "unable to eat a lot of types of food" (for the "eating" item), and from "not at all difficult" to "extremely difficult" (for the other items)	Day 0, +1, +2, +3, +4, +7 and +14 following surgery
Secondary	Incidence of postoperative signs and symptoms	Incidence of postoperative signs and symptoms (i.e., swelling, nausea, bruising, bad taste/smell) at day 0 (evening), +1, +2, +3, +4, +7 and +14	Day 0, +1, +2, +3, +4, +7 and +14 following surgery
Secondary	Willingness to undergo the same type of surgery	Willingness to undergo the same type of surgery, recorded at day +14 on a 4-point rating scale ranging from "no problem to repeat surgery if needed" to "I will never undergo this type of surgery again."	Day +14 following surgery